Is adjuvant chemotherapy indicated in stage i pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 48-52

  Mangili, G ^a   Scarfone, G ^b   Gadducci, A ^c   Sigismondi, C ^a   Ferrandina, G ^d   Scibilia, G ^e   Vigano R ^a   Tateo, S ^f   Villa, A ^b   Lorusso, D ^g  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e CANNIZZARO HOSPITAL   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemotherapy; Immature teratoma; Recurrence; Stage I; Surveillance

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADOLESCENT; ADULT; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CYSTECTOMY; DISEASE ASSOCIATION; DRUG TOLERABILITY; FEMALE; FERTILITY; FOLLOW UP; HUMAN; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVARY TERATOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; STUDENT T TEST; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; OVARIAN NEOPLASMS; PATHOLOGY; TERATOMA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TERATOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956648494     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.05.035     Document Type: Article

References (33)

1. J.T. Quirk, N. Natarajan, and C.J. Mettlin Age-specific ovarian cancer incidence rate patterns in the United States Gynecol Oncol 99 2005 248 250 (Pubitemid 41354614)
2. FIGO Cancer Committee Staging announcement Gynecol Oncol 25 1986 383
3. H.J. Norris, H.J. Zirkin, and W.L. Benson Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases Cancer 37 1976 2359 2372
4. S.J. Robboy, and R.E. Scully Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases Hum Pathol 1 1970 643 653
5. D.M. Gershenson, G. del Junco, E.G. Silva, L.J. Copeland, F.N. Wharton, and F.N. Rutledge Immature teratoma of the ovary Obstet Gynecol 68 1986 624 629
6. J.P. Koulos, J.S. Hoffmann, and M.M. Steinhoff Immature teratoma of the ovary Gynecol Oncol 34 1989 46 49
7. D.M. Gershenson, M. Morris, A. Cangir, J.J. Kavanagh, C.A. Stringer, and C.L. Edwards Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin J Clin Oncol 8 1990 715 720
8. M. Kawai, T. Kano, Y. Furuhashi, M. Iwata, N. Nakashima, and N. Imai Immature teratoma of the ovary Gynecol Oncol 40 1991 133 137
9. S. Williams, J.A. Blessing, S.Y. Liao, H. Ball, and P. Hanjani Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide and bleomycin: a trial of the Gynecology Oncology Group J Clin Oncol 12 1994 701 706
10. K.H. Lu, and D.M. Gershenson Update on the management of ovarian germ cell tumors J Reprod Med 50 2005 417 425
11. K. Tewari, F. Cappuccini, P.J. Disaia, M.L. Berman, A. Manetta, and M.F. Kohler Malignant germ cell tumors of the ovary Obstet Gynecol 95 2000 128 133
12. U.B. Chaudhary, and J.R. Haldas Long-term complications of chemotherapy for germ cell tumours Drugs 63 2003 1565 1577
13. M.M. Troost, C.N. Sternberg, and R. de Wit Management of good risk germ-cell tumours BJU Int 104 2009 1387 1391
14. L.B. Travis, S.D. Fossa, and S.J. Schonfeld Second cancers among 40576 testicular cancer patients: focus on long-term survivors J Natl Cancer Inst 97 2005 1354 1365
15. A. Van den Belt-Dusebout, R. de Wit, J. Gietema, S. Horenblas, M.W. Louwman, and J.G. Ribot Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 25 2007 4370 4378
16. B.H. Zoltick, L.A. Jacobs, and D.J. Vaughn Cardiovascular risk in testicular cancer survivors treated with chemotherapy: incidence, significance, and practice implications Oncol Nurs Forum 32 2005 1005 1009 (quiz 1010-1)
17. C. Boshoff, R.H. Begent, R.T. Oliver, G.J. Rustin, E.S. Newlands, and R. Andrews Secondary tumours following etoposide containing therapy for germ cell cancer Ann Oncol 6 1995 35 40
18. J. Wierecky, C. Kollmannsberger, I. Boehlke, M. Kuczyk, J. Schleicher, and N. Schleucher Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer J Cancer Res Clin Oncol 131 2005 255 260
19. E. Azambuja, J.F. Fleck, and R.G. Batista Menna Barreto SS. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther 18 2005 363 366
20. J.T. Hartmann, C. Kollmannsberger, L. Kanz, and C. Bokemeyer Platinum organ toxicity and possible prevention in patients with testicular cancer Int J Cancer 83 1999 866 869
21. D. Matei, A.M. Miller, P. Monahan, D. Gershenson, Q. Zhao, and D. Cella Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4142 4149
22. D.M. Green, C.A. Sklar, J.D. Boice Jr, J.J. Mulvihill, J.A. Whitton, and M. Stovall Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study J Clin Oncol 27 2009 2374 2381
23. S.C. Yoo, W.Y. Kim, J.H. Yoon, S.J. Chang, and K.H. Chang Ryu HS.Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy Acta Obstet Gynecol Scand 89 2010 126 130
24. D.M. Gershenson, A.M. Miller, V.L. Champion, P.O. Monahan, Q. Zhao, D. Cella, S.D. Williams Gynecologic Oncology Group Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 2792 2797
25. J. Tangir, D. Zelterman, W. Ma, and P.E. Schwartz Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary Obstet Gynecol 101 2003 251 257
26. G. Zanetta, C. Bonazzi, M. Cantù, S. Binidagger, A. Locatelli, and G. Bratina Survival and reproductive function after treatment of malignant germ cell ovarian tumors J Clin Oncol 19 2001 1015 1020
27. J.J. Low, L.C. Perrin, A.J. Crandon, and N.F. Hacker Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases Cancer 89 2000 391 398
28. C. Bonazzi, F. Peccatori, N. Colombo, V. Lucchini, M.G. Cantù, and C. Mangioni Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients Obstet Gynecol 84 1994 598 604
29. P.L. Mitchell, N. Al-Nasiri, R. A'Hern, C. Fisher, A. Horwich, and C.R. Pinkerton Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases Cancer 85 1999 2232 2244
30. B. Cushing, R. Giller, A. Ablin, L. Cohen, J. Cullen, and E. Hawkins Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group Am J Obstet Gynecol 181 1999 353 358 (Pubitemid 29409913)
31. D.M. Patterson, N. Murugaesu, L. Holden, M.J. Seckl, and G.J. Rustin A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites Int J Gynecol Cancer 18 2008 43 50
32. G. Palenzuela, E. Martine, A. Meunier, P. Beuzeboc, V. Laurence, and D.E. Orbach Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary Ann Surg 248 2008 836 841
33. D.M. O'Connor, and H.J. Norris The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading Int J Gynecol Pathol 13 1994 283 289